Information Provided By: 
Fly News Breaks for October 30, 2015
MDXG
Oct 30, 2015 | 06:53 EDT
Northland analyst Mark Landy upgraded MiMedx to Outperform saying yesterday's selloff after the FDA released proposed draft guidance on homologous use of human cells and tissue-based products is a buying opportunity. Investors sold the stock on concerns that the FDA may remove MiMedx product from the market, Landy tells investors in a research note. He views the risk of product removal as low and has an $11 price target for MiMedx shares.
News For MDXG From the Last 2 Days
There are no results for your query MDXG
